Letters

Dornase alfa for cystic fibrosis

BMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7008.813 (Published 23 September 1995) Cite this as: BMJ 1995;311:813
  1. Glenn Robert,
  2. Andrew Stevens,
  3. Duncan Colin-Jones
  1. Research assistant Senior lecturer in public health medicine Wessex Institute of Public Health Medicine, Winchester SO22 5DH
  2. Chairman, development and evaluation committee Queen Alexandra Hospital, Cosham, Portsmouth PO6 3LY

    EDITOR,--The use of dornase alfa has been a topic of recent controversy.1 2 3 South and West region's development and evaluation committee of senior clinicians supported by a research review team undertook to determine the drug's cost effectiveness on the basis of the published evidence.4 The net cost (total costs less savings) to the NHS of prescribing a daily dose of 2.5 mg of dornase alfa to patients with cystic fibrosis in the former Wessex Regional Health Authority, excluding children under …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe